-
Founded in:
2001-08-17 -
Country:
China -
Address:
No. 802, South Section of Rainbow Avenue, Dujiangyan City, Chengdu City, Sichuan Province -
Tax NO.:
91510181730231740X -
Registered Funds:
50 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Azithromycin |
Azithromycin is a 15-membered macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. Its mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of bacterial ribosomes and inhibiting RNA-dependent protein synthesis.
More
Azithromycin is a 15-membered macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. Its mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of bacterial ribosomes and inhibiting RNA-dependent protein synthesis. |
83905-01-5 | 39 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Zoledronic acid |
Inhibition of bone resorption may be related to multiple effects. Zoledronic acid can inhibit osteoclast activity in vitro, induce osteoclast apoptosis, block osteoclast absorption of mineralized bone and cartilage by binding to bone, and inhibit the enhanced osteoclast activity and bone calcium release caused by various stimulating factors released by tumors.
More
Inhibition of bone resorption may be related to multiple effects. Zoledronic acid can inhibit osteoclast activity in vitro, induce osteoclast apoptosis, block osteoclast absorption of mineralized bone and cartilage by binding to bone, and inhibit the enhanced osteoclast activity and bone calcium release caused by various stimulating factors released by tumors. |
118072-93-8 | 37 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Simvastatin |
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.
More
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease. |
79902-63-9 | 63 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Simvastatin |
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.
More
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease. |
79902-63-9 | 63 |